IOTA Pharmaceuticals

Email Usinfo@iotapharma.com

IOTA Pharmaceuticals
Fragment - based Drug Discovery
Neglected Parasitic Disease
Glioma & Glioblastoma
WINDOW on Glioblastoma
 
 
IOTA Pharmaceuticals
December 11, 2017
 

IOTA scientists review the impact of phenotypic profiling in GBM drug discovery and patient stratification

IOTA scientists Dr David Bailey and Dr Fredrik Svensson review recent developments in phenotypic screening techniques with potential clinical applications in treating GBM. Read the paper here.


Back
RSS